4/24
10:15 am
howl
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/24
10:05 am
howl
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Medium
Report
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
4/23
08:12 am
howl
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting [Yahoo! Finance]
4/23
08:00 am
howl
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Medium
Report
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
4/15
01:57 pm
howl
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy [Yahoo! Finance]
4/5
04:38 pm
howl
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting [Yahoo! Finance]
High
Report
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting [Yahoo! Finance]
4/5
04:30 pm
howl
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Medium
Report
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
4/4
04:45 pm
howl
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting [Yahoo! Finance]
Low
Report
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting [Yahoo! Finance]
4/4
04:30 pm
howl
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
Low
Report
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4/3
08:08 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $12.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $12.00 price target on the stock.
3/7
10:50 am
howl
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
3/7
07:16 am
howl
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/7
07:00 am
howl
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/6
08:00 am
howl
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
Low
Report
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
3/5
04:30 pm
howl
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
Low
Report
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024